Reducing progression of experimental lupus nephritis via inhibition of the B7/CD28 signaling pathway.

The aim of the present study was to evaluate the effects of the B7/cluster of differentiation (CD)28 signaling pathway on experimental lupus nephritis and examine the molecular mechanism involved by inhibiting the B7/CD28 signaling pathway. A lupus nephritis model in C57BL/6 J mice was induced via intraperitoneal injection of pristane. A recombinant B7­1 short hairpin RNA (shRNA) lentivirus vector was constructed by synthesis and splicing. A neutralizing mouse anti­human B7­1 antibody termed 4E5 was also prepared. The mouse model of lupus nephritis was treated with B7­1 shRNA and 4E5 via injection through the tail vein. The silencing effects of B7­1 shRNA lentiviral infection on target molecules were evaluated using immunofluorescence and flow cytometry. The levels of protein in the urine were detected using Albustix test paper each month over 10 months. The concentration of interleukin (IL)­4 and interferon­Î³ in the serum was determined using an ELISA. The immune complex (IC) deposits in the kidney were analyzed using direct immunofluorescence. The results demonstrated that the C57BL/6 J mouse lupus nephritis model was successfully constructed with immune cells activated in the spleen of the mice, increases in the concentration of anti­nuclear antibody (ANA) and anti­double stranded DNA antibodies as well as positive IC formation. Following B7­1 shRNA lentivirus or 4E5 treatment, CD11b+B7­1+, CD11c+B7­1+ and CD21+B7­1+ cells in the spleen of the mice were significantly reduced. The concentration of ANA and IL­4 in the serum was also decreased. The concentration of urine protein was reduced and it was at its lowest level in the 4E5 early intervention group. It was also revealed that the immunofluorescence intensity of the IC deposits was weak in the 4E5 early intervention group. In conclusion, inhibiting the B7­1/CD28 signaling pathway is able to alleviate experimental lupus nephritis and provides an experimental basis for the therapeutic use of blocking the B7­1/CD28 signaling pathway in human lupus nephritis and other autoimmune disorders.

[Construction of 3D model of CD28 chimeric antibody with its antigen docked].

AIM: To construct a 3D model of the chimeric antibodies (AntiCD28: ch-2F5) with corresponding antigen molecule docked to theoretically verify the rationality of the binding of antibody with its antigen and to provide a method of 3D identification between antigen and antibody and spatial structure analysis. METHODS: We analyzed the sequence by submitting it to http://www.ncbi.nlm.nih.gov/ and made a comparison using integratly the 3 databases of GenBank, Protein data bank and GENO-3D. The 3D model was constructed by Swiss-model homology modeling server and molecular docking online was performed by GRAMM-X Protein Docking Web Server. Chimeric heavy chain, light chain, heavy-light chain complex, heavy-light chain and antigen complex were displayed and photographed by the Chimera Software. Meanwhile, the spatial structures of heavy, light chains, variable region, constant region, CDR and frame area were marked by different colours respectively to exhibit the 3D structure on every side. RESULTS: The 3D structure of the heavy-light chain and antigen complex we constructed was consistent well with the theory of antigen binding to antibody molecules. CONCLUSION: The structure of the chimeric antibody we constructed with the bioinformatic method was in accordance with the general structure of antibody, and its antigen binding site was also consistent with the molecular theory. Thus, the model helps to analyze the 3D structure of antibody and antigen-antibody interaction.

[Expression and antigen binding activity of anti-human CD86 diabody].

AIM: To construct a recombinant eukaryotic expression vector of anti-human CD86 diabody gene and express anti-CD86 diabody through Chinese hamster ovary (CHO) cells, then analyze the capability of the diabody to recognize the tumor cells expressing CD86 and its biological effect. METHODS: The antibody heavy and light chain viable region gene (V(H); and V(L);) were cloned from hybridoma cell 1D1 which secreted anti-human CD86 monoclonal antibody. Anti-human CD86 diabody gene V(H);-(GGGGS)-V(L); was constructed by SOE-PCR. Then we inserted it into eukaryotic expression vector to construct a recombinant vector pIRES2-EGFP/CD86-diabody. The recombinant vector was transfected into CHO cells with Lipofectamine(TM); 2000, and the cell clones secreting CD86 diabody were screened by G418. We used IMAC to purify CD86 diabody and quantified its concentration by BCA method. The capability of the diabody to recognize the CD86 expressed on Raji and Daudi was analyzed through flow cytometry. After Raji cells were treated with CD86 diabody for 72 h, its proliferation inhibiting effect was investigated by MTT assay. RESULTS: We have obtained one CHO cell line that stably secreted CD86 diabody. The concentration of CD86 diabody after purification was 5.24 mg/L. The positive rates of CD86 diabody to recognize Raji and Daudi were 77.2% and 70.6%, respectively. After CD86 diabody treatment for 72 h, the inhibition rate of Raji cells was 37%. CONCLUSION: The anti-human CD86 diabody which we obtained successfully could recognize CD86 expressed on tumor cells specifically, and inhibit the proliferation of these tumor cells effectively.

[Effect of CD80-scFv on recognition of CD80 molecule and proliferation of different tumor cells in vitro].

AIM: To prepare CD80-scFv in CHO cells and investigate its effect on the recognition and proliferation of different tumor cells. METHODS: The CD80-scFv was purified from culture supernatant without fetal calf serum (FCS) by IMAC affinity chromatography, and then bound to CD80 molecule on the Daudi, U251, A375 and 8266 cells detected by flow cytometry. Different concentrations of CD80-scFv were added in the training system of different tumor cells, and we analyzed the influence on the proliferation of these cells by MTT assay. With 8266 cells which expressed CD80 highly and were treated by mitomycin firstly as the APC, and human PBMC as the effect cells, we analyzed the influence of the CD80-scFv on the proliferation of PBMC by blocking the co-stimulatory signal. RESULTS: The concentration of CD80-scFv purified from FCS was about 6.67 mg/L and the binding rate of CD80-scFv with Daudi, U251, A375, 8266 and U266 were 96.8%, 39.6%, 20.5%, 99.9% and 3.8%, respectively. CD80-scFv suppressed the proliferation of Daudi and 8266 cells which expressed CD80 highly, and the inhibition rate of Daudi and 8266 cells cultured with CD80-scFv (the final concentration was 25 µg/mL) was 24.04% and 24.16%, respectively. Additionally, the antibody suppressed the proliferation of PBMC by blocking the co-stimulatory signal mediated by CD80-CD28. CONCLUSION: CD80-scFv can recognize CD80 molecule and suppress the proliferation of tumor cells which express CD80 highly.

[Changes in the expression of T lymphocyte subsets in ageing mice induced by D-galactose].

AIM: To explore the changes and significance of spleen T cell subsets in ageing mice induced by D-galactose. METHODS: Ageing mice model was successfully established by 100 g/L D-galactose. The content of IFN-γ and IL-4 in serum was measured by ELISA. T cell subsets were detected by Immunofluorescence technique and flow cytometry. RESULTS: The content of IFN-γ and IL-4 in the serum was decreased of model group (P<0.01). The naive T cell related molecule, CD45RA was decreased(P<0.05). T cell activation-related molecule, CD25 was decreased(P<0.05). The Foxp3 in CD4(+);CD25(+); T cell was increased(P<0.01). CONCLUSION: In spleen of the ageing mice, the percentage of naive and active T cell are decreased, but The percentage of CD4(+); Tr subset is increased.

[Changes and effects of significant membrane molecules on thymic T cell of aging mice induced by D-galactose].

AIM: To establish subacute aging mice model by D-galactose and to explore the changes and effects of significant membrane molecules on thymic T cell. METHODS: Female Kunming mice of 8 weeks old were injected with D-galactose of 12.5 mL/(kg.d) by subcutaneous in scruff for 42 days. The animals' living conditions and biological behaviors were observed everyday.SOD activities and MDA content of serum were measured to determine whether the aging model was successfully established.On the basis of successfully establishing aging model, detect the significant membrane molecules of thymic T cell by Immunofluorescence technique and Flow Cytometer. RESULTS: During the 42 days, gradually, the model mice showed bending body, loose skin, slow action and so on.The activities of SOD in the serum were significantly decreased(P<0.01), and the content of MDA in the serum was significantly increased(P<0.01). The thymic naive T cell significant molecule, CD45RA was decreased(P<0.05). T cell activation-related molecules, CD28 and CD25 were both decreased(P<0.05), and PD-1 was significantly increased(P<0.01). The memory T cell significant molecule, CD196 was increased, but was not significantly compared to the control mice. CONCLUSION: The D-galactose subacute aging mice model was successfully established.The naive and active T cell were decreased and the memory T cell was increased in the thymic of the aging.

[The changes of spleen B cells of D-galactose-induced aging mice].

AIM: This paper is to analyze the changes of important membrane type molecules of the spleen B cells and their significance on the basis of biology identification by establishing subacute aging mice model with D-galactose. METHODS: Health Kunming mice are injected with 100 ng/L D-galactose, 0.25 mL/20 g, once per day, for 42 days consecutively, into their back necks. The animals' living conditions and biological behaviors are observed everyday and the dynamic changes of their weight are measured regularly. The biology identification of aging model mice is conducted by means of measuring the SOD viability and malondialdehyde (MDA) concentration in serum; the analysis of the activation- and memory-related important membrane type molecules of spleen cells is carried out with immune fluorescence and flow cytometry; the analysis of the concentration of IL-4 in serum is conducted by ELISA. RESULTS: Building a successful subactue aging mice model.The results of immune fluorescence and flow cytometry showed that CD20(+); was 56.8%, CD40(+); was 43.6%, CD20(+);CD45RA(+);B was 14.04%, CD40(+);CD45RA(+);B was 35.4%, CD20(+);CD86(+);B was 2.25%, CD40(+);CD86(+);B was 4.38%, CD20(+);CD196(+);B was 10.68%, and CD40(+);CD196(+);B was 10.98%. The results of ELISA showed that the average level of IL-4 in serum was 7.93 ng/L. The statistical analysis showed that the expressions of CD20, CD40, CD45RA, and CD86 of the spleen cells of the model control group and the average level of IL-4 in serum were lower than the normal control group(P<0.05)while CD196 was higher than the normal control group(P<0.01). CONCLUSION: In the body's aging process, the expressions of the activation- and memory-related important membrane type molecules of spleen cells change, activated cells reduce, memory cells increase, and the expression of IL-4 in serum drop, resulting in the immune system function disorder.

[Construction of human CXCR3B gene transfected cell line, identification and study of its biological function].

AIM: To construct recombinant human CXCR3B gene expression vector and obtain L929-CXCR3B gene transfected cell line for stably expressing human CXCR3B. METHODS: Human CXCR3B gene of full length was amplified by PCR from the plasmid pMD19-T/huCXCR3A. Then, it was inserted into eukaryotic expression vector pIRES2-EGFP to construct recombinant vector pIRES2-EGFP/huCXCR3B. The recombinant vector was transfected into L929 cells with Lipofectamine(TM); 2000, and cell clones stably expressing human CXCR3B molecule were screened by G418.We used FCM and RT-PCR to verify expression of CXCR3B from protein level and gene level. The ability of proliferation of L929-huCXCR3B under the circumstance of CXCR3B ligand called Mig was analyzed via MTT methods. RESULTS: We have constructed recombinant human CXCR3B gene expression vector and obtained L929-huCXCR3B gene transfected cell line which can stably express human CXCR3B molecule. The positive expression rate of CXCR3B on L929-huCXCR3B cells was 93&. The result of MTT assay showed that the proliferation of L929-huCXCR3B cells were inhibited when the cells were cocultured with Mig after 24 h, 48 h and 72 h, and the inhibition ratio were 41.44&, 44.01& and 24.80& respectively. CONCLUSION: Construction of L929-huCXCR3B cell line has laid a good foundation on research of the CXCR3B signal pathway and preparation of the CXCR3B monoclonal antibody.

[Mouse anti-human CXCR3 mAb preparation and its biological function].

AIM: Obtain hybridoma cell line with continuing expression of mouse anti-human CXCR3 mAb, investigate expression characteristics of human CXCR3 and how CXCR3 signal transduction function on L929-huCXCR3 and colon carcinoma cell lines transfer and growth. METHODS: Taking L929-huCXCR3 cell with high expression of human CXCR3 membrane molecule as immunogen to immunize BALB/c mouse, we fused immunized mouse spleen cell with myeloma cell Sp2/0 of its same germ line, then used L929-huCXCR3 as screening cell and empty vector transfected cell L929-mock as negative control. Obtained hybridoma cell line with continuing secretion of anti-human CXCR3 mAb through flow cytometry. We used Ig subclass type rapid qualitation indicator paper method and indirect immunofluorescence to identify obtained hybridoma cell line and mAb, indirect immunofluorescence to analyze CXCR3 expression on tumor cell surface, Transwell isolation cabin to assess effect on L929-huCXCR3 and colon carcinoma cell line Colo205, HCT116 and HT29 migration by mAb, MTT method to analyze how mAb function on colon carcinoma cell line Colo205 proliferation. RESULTS: Obtained a hybridoma cell line with continuing secretion of mouse anti-human CXCR3 mAb, named 9B5. According to rapid qualitation test paper analysis, light chain of the mAb was chain and heavy chain is IgG1 subclass. Indirect immunofluorescence and flow cytometry results show that the mAb can recognize CXCR3 molecules on the surface of activated T lymphocyte and colon carcinoma cell line Colo205, HCT116 and HT29 cell. mAb 9B5 can inhibit oriented migration of L929-huCXCR3 cells, colon carcinoma cell line Colo205, HCT116 and HT29 cell, it can also inhibit Colo205 growth promotion effect by IP-10. CONCLUSION: Successfully obtain a hybridoma cell line with continuing secretion of mouse anti-human CXCR3 mAb, which has laid material foundation on investigation of CXCR3 expression characteristics and CXCR3 signal transduction function on tumor growth and migration. It is prospective to create a new way and a new drug for treatment of tumor metastasis.

[Dynamic changes of early immune responses to attenuated Schistosoma japonicum cercariae induced in BALB/c mice].

OBJECTIVE: To study the early immune activation and its dynamic changes between the attenuated cercariae immunized mice and the normal infected mice. METHODS: The dendritic cell surface molecules CD11c and T cell surface molecule CD25 expression differences and CD3+CD25+/CD3+ T ratio of the early spleen and/or lung of the attenuated cercariae immunized mice and normal mice were assayed and compared by FCM and IHC, and the immune activation and dynamics of T cells were analyzed. RESULTS: CD3+CD25+CD3+ T ratio in the spleen cells 7 days post-infection in the immunized group and the normal infected group were (19.52 +/- 3.65)% and (22.12 +/- 3.24)%, respectively; the rates of 14 days and 21 days post-infection were (28.73 +/- 3.94)%, (13.68 +/- 3.64)% and(26.43 +/- 0.40)%, (14.42 +/- 2.24)%, respectively. The expressions of CD11c+DC in the lung of the two groups were (1.05 +/- 0.16)%, (0.96 +/- 0.15)%, (1.34 +/- 0.15)%, (1.09 +/- 0.17)%, (1.49 +/- 0.14)%, (0.97 +/- 0.16)%, respectively; the expressions in the spleen were (2.05 +/- 0.26)%, (1.95 +/- 0.18)%, (2.24 +/- 0.25)%, (2.17 +/- 0.25)%, and (2.18 +/- 0.26)%, (2.06 +/- 0.18)%, respectively, on the 7, 14 and 21 days post-infection. The expressions of CD25+T cells in the lung of the two groups were (1.24 +/- 0.13)%, (1.17 +/- 0.16)%, (1.48 +/- 0.11)%, (1.25 +/- 0.13)%, and (1.55 +/- 0.14)%, (0.97 +/- 0.12)%, respectively; the expressions in the spleen were (3.25 +/- 0.22)%, (2.93 +/- 0.20)%, (4.57 +/- 0.23)%, (3.69 +/- 0.24)% and (4.28 +/- 0.24)%, (3.86 +/- 0.26)%, respectively, on the 7, 14 and 21 days post-infection. The CD3+CD25+/CD3+T rate in the infection control group was significantly higher than that in the cercariae attenuated group, while 14, 21 days post-infection the rates of the attenuated group were significantly higher than those in the normal control group. On the 7, 14 and 21 days post-infection, the lung tissue of the attenuated cercariae immunized mice raised more CD11c+ DC and CD25+ T cells than that of the normal infected mice did. CONCLUSIONS: The activation of T cells of the immune group and the activation of pulmonary dendritic cells are higher than those in the control group 7 and 14 days post-infection, suggesting that attenuated cercariae in the lungs can raise more antigen presenting cells and their activation.

A novel monoclonal antibody against human CD80 and its immune protection in a mouse lupus-like disease.

Blockade of the interactions between CD28/CTLA-4 and their ligands, CD80 (B7, B7.1)/CD86 (B70, B7.2), is an attractive means to induce antigen-specific peripheral tolerance in autoimmune disease and organ transplantation. In this study, we generated and characterized a monoclonal antibody (Clone 4E5) against human CD80. 4E5 could recognize both human and mouse CD80 and suppress mixed lymphocyte reaction in vitro. To investigate their potency for clinical use, we further administrated 4E5 to a mouse lupus-like disease model (C57BL/J6) induced by Pristane. 4E5 could inhibit the immune response and attenuate the severity of lupus-like disease. The data showed 4E5 function and suggested that blockade of CD80/CD28 co-stimulatory signal pathway with 4E5 is a promising strategy to decelerate the progression of lupus-like disease and other autoimmune diseases.

[Construction of murine CXCR3 gene transfected cell line, identifiction and study of its biological function].

AIM: To construct recombinant murine CXCR3 gene retroviral vector and obtain L929-mCXCR3 gene transfected cell line for stably expressing murine CXCR3. We further study on L929-mCXCR3 migration effect resulted from interaction by CXCR3 and its ligand IP-10. METHODS: One female BALB/c mouse (7 weeks) was injected with 0.5 mg Con A intravenously (i.v.) via a tail vein. Twelve hours later the mouse was sacrificed and the spleen was removed.The spleen was pressed through a 150 microm stainless steel mesh. The isolated splenocytes were cultured in RPMI1640 supplemented with 50 U/mL human IL-2 for 3 days.Total RNA was extracted with TRIzol. Murine CXCR3 gene of full length was amplified by RT-PCR, then, it was inserted into retrovirus vector pEGZ-term. The recombinant vector together with its helper virus vector were co-transfected into package cell 293T with Lipofectamine(TM); 2000.The supernatant of 293T was collected for infecting L929 cells (repeated three times), and cell clones stably expressing murine CXCR3 molecule were screened by zeocin(500 mg/L). We used FCM and RT-PCR to verify expression of CXCR3 from protein level and gene level, respectively. Studied migration ability of L929-mCXCR3 interacted with its ligand IP-10 by transwell system. RESULTS: We have constructed recombinant murine CXCR3 gene retroviral vector and obtained L929-mCXCR3 gene transfected cell line which can stably expressing murine CXCR3 molecule. Positive expression rate of membrane is 97.0%, and it can directly migrate induced by IP-10, the chemotatic index is 4.356%. CONCLUSION: Construction of L929-mCXCR3 cell line has laid a good foundation on research of biologic characteristics of CXCR3 signal path , establishment of tumor metastasis model and preparation of anti-murineCXCR3 monoclonal antibody.

[Inhibitory and lethal effects of human-mouse chimeric antibody against CD80 on the growth of B lymphoma cell lines Raji and Daudi].

AIM: To study the inhibitory and lethal effects of human-mouse chimeric antibody against CD80 (named ch-4E5) on the growth of B lymphoma cell lines Daudi and Raji. METHODS: Immunofluorescence and flow cytometry were used to analyze the detection of membrane CD80 in Raji and Daudi by ch-4E5. After the co-culture of ch-4E5 with Raji and Daudi, respectively, at the final concentration of 10 mg/L, the expression of Fas and FasL was observated to be at the 0 h, 4 h, 10 h, 16 h, 24 h and 48 h by direct immunofluorescence and flow cytometry, and the blocking effect on cell growth of ch-4E5 was determined at 72 h by MTT assay. MTT assay was also used to study the ADCC effect with PBMC as effector cells and Raji and Daudi as target cells. The efficiency target ratio was 20:1. RESULTS: The combination rate between ch-4E5 and Raji and Daudi was 98.6% and 96.4%, respectively. After the co-culture of ch-4E5 with Raji and Daudi cells for 4 hs, the expression of FasL in Raji began to up-regulate. It reached the peak at 16 h and its positive rate was 16.8%. Compared with human IgG1 control group, it was increased obviously (P<0.01). The expression of Fas increased at 10 h, and then reached the top at 24 h. The combination rate was 15.6%. There was significant deviation compared with human IgG1 control group (P<0.01). Moreover, the expression of FasL and Fas on Daudi was also altered. The trend was similar to these on Raji, and the highest expression was 15.9% and 13.7%, respectively. The inhibitory rate was 34.60% and 32.64% respectively when ch-4E5 with Raji and Daudi had been co-cultured for 72 h (P<0.01). Furthermore, ch-4E5 could mediate the ADCC effect and the maximum killing rate was 55.61% and 54.42%, respectively(P<0.01). CONCLUSION: The human-mouse chimeric antibody against CD80 can inhibit the proliferation of B lymphoma cell lines Daudi and Raji cells through Fab and Fc sections in vitro.

[Preparation of two mouse anti-human PD-1 monoclonal antibodies and identification of their biological characteristics].

AIM: To prepare mouse anti-human PD-1 monoclonal antibodies (mAbs) and identify their biological characteristics. METHODS: The BALB/c mice were immunized with the transfected cell line PD-1/L929. The cells were fused with Sp2/0 using monoclonal antibody techniques and the positive clones were screened by FCS with PD-1/L929. The secreted anti-PD-1 mAbs were identified through rapid isotyping analysis, karyotype analysis, Western blot, competitive inhibition test, indirect immunofluorescence assay, and tumor cell lines detection. RESULTS: Two mouse anti-human PD-1 hybridomas were obtained and their secreted mAbs were named (1F2 and 5F10). Their biological characteristics suggested that they could recognize a protein with approximate molecular weight 55 000 on PD-1/L929 cell lines and different epitopes. 1F2 could recognize PD-1 molecules expressed on SKHep-1 and 7721 while 5F10 could recognize Raji cells. CONCLUSION: Two mouse anti-human PD-1 hybridoma cell lines and their secreted monoclonal antibodies have been successfully obtained and identified.

Preparation and characterization of a novel chimeric antibody against human CD40 with the potential to inhibit Daudi cell proliferation.

5C11, a murine monoclonal antibody with a high specificity for human CD40 molecule, is a promising candidate for cancer targeting therapy. We have therefore attempted to construct a humanized antibody of 5C11 to minimize its immunogenicity for potential clinical use. A chimeric version of 5C11 (ch-5C11) was generated by transferring these mouse variable regions onto a human framework. This chimeric antibody retained reactivity to human CD40. In vitro, ch-5C11 could effectively inhibit B lymphoma Daudi cell proliferation, suggesting that it might have the potential to be developed for future clinical use.

Effects of preemptive intravenous lornoxicam on the analgesic efficacy of epidural morphine and expression of chemokines in women undergoing hysterectomy.

BACKGROUND: It is believed that preemptive IV lornoxicam treatment can reduce the consumption of other analgesics, improve analgesic efficacy, and ameliorate immune function during patient-controlled IV analgesia. However, the effects of preemptive IV lornoxicam treatment on the analgesic efficacy of patient-controlled epidural analgesia (PCEA) with morphine and on chemokine expression remain unknown. OBJECTIVE: The aim of this prospective, randomized, controlled study was to observe the effects of preemptive IV lornoxicam treatment on the analgesic efficacy of PCEA with morphine and on the expression of monocyte chemotactic protein-1 (MCP-1) and stromal cell-derived factor-1α (SDF-1α) in women undergoing hysterectomy. METHODS: Patients undergoing elective hysterectomy with combined spinal and epidural anesthesia were randomized to 1 of 3 groups to receive IV lornoxicam 8 mg before anesthesia (group 1), lornoxicam 16-mg injection before anesthesia (group 2), or isotonic saline (control) before anesthesia. PCEA was used to treat postoperative pain, and a visual analog scale (VAS) and the Bruggemann Comfort Scale (BCS) were used to evaluate analgesic efficacy. Morphine consumption was recorded. To measure plasma concentrations of MCP-1 and SDF-1α via enzyme-linked immunosorbent assay, venous blood samples were obtained from patients at 4 separate times: before anesthesia (baseline); 0 (immediately after anesthesia administration); and 24 and 48 hours after surgery. RESULTS: Forty-five patients (mean [SD] age, 41 [5] years; mean [SD] weight, 54 [6] kg) undergoing elective hysterectomy were included in the study. There were no significant differences in VAS scores, BCS scores, or morphine consumption between the 3 groups. Compared with baseline values, MCP-1 and SDF-1α concentrations were increased significantly immediately after surgery in all 3 groups (all, P < 0.01) and returned to near-baseline values at 24 hours postsurgery in groups 1 and 2, and by 48 hours postsurgery in the control group. MCP-1 and SDF-1α concentrations in groups 1 and 2 were significantly lower than those in the control group immediately (all, P < 0.01) and 24 hours postsurgery (all, P < 0.05). CONCLUSION: Preemptive IV lornoxicam treatment was associated with attenuation of the plasma concentrations of MCP-1 and SDF-1α immediately after and 24 hours after hysterectomy and was associated with more rapid resolution to near-baseline concentrations of both cytokines in these patients compared with controls; however, it was not associated with significantly reducing epidural morphine consumption.

Fine-tuned expression of programmed death 1 ligands in mature dendritic cells stimulated by CD40 ligand is critical for the induction of an efficient tumor specific immune response.

During maturation, murine myeloid dendritic cells (DCs) upregulated the expressions of CD11c, CD25, CD40, CD80, CD86, MHC II and programmed death 1 ligands 1 and 2 (PD-L1 and PD-L2). Differential expression patterns of PD-L1 and PD-L2 were found when DCs were triggered by CD40 ligand and TNF-alpha. PD-L1 expression was repressed and PD-L2 expression remained unchanged in mature CD40-ligated DCs, whereas TNF-alpha stimulated DCs kept high expression of PD-L1 and significantly enhanced PD-L2 expression on DCs. Proliferations of T lymphocytes stimulated by immature DCs were enhanced by blockade of the PD-1 and PD-1 ligand interaction. But inhibitive effects were found in T lymphocytes stimulated by CD40-ligated DCs. With the fine-tuned expressions of PD-L1 and PD-L2, CD40-ligated DCs could sustain a longer activation period and elicit a more efficient T lymphocyte activation.

[Construction of anti-CD28 single chain antibody genes and expression of the ScFv in BmN cells and the larvae of Bombyx mori].

The V(H) and V(L) gene fragments of anti-CD28 mAb were combined to form anti-CD28 ScFv gene by using TP-PCR method. Sequence analysis showed that 6 x His tag was added to it for the ease of purification and the V(H), and V(L) gene fragments were connected by a linker containing 15 amino acids which are biased by the baculovirus promoter, ph. Then ScFv gene fragment was inserted into baculovirus transfer vector pBacPAK8. The recombinant transfer vector, pBacPAK8/CD28-ScFv was constructed successfully. The pBacPAK8/CD28-ScFv and the linear Bm-BacPAK6 were co-transfected into the cell line of Bombyx mori (BmN) with the help of Lipofectin,then the product was purified by plaque assay and identified by PCR method. The recombinant virus, Bm-BacPAK6 CD28-ScFv, was obtained successfully. The BmN cells and the larvae of Bombyx mori were infected by the recombinant baculovirus and harvested every 24h postinfection. SDS-PAGE and Western Blotting analysis confirmed the expression of ScFv with the molecular weight of about 28 kD. The expression in BmN cells was detected 24h post infection and it peaked at 72 h, while in the larvae of Bombyx mori, the expression was detected 48 h post infection and it peaked at 120 h.

A novel anti-human syndecan-1 (CD138) monoclonal antibody 4B3: characterization and application.

Syndecan-1 (CD138), a member of integral membrane heparin sulfate proteoglycans, is an essential matrix receptor for maintaining the normal morphological phenotypes. In this study, we generated a specific mouse anti-human syndecan-1 monoclonal antibody (mAb) 4B3 and identified it by competition assay with the available syndecan-1 mAb (BB4). Stained by 4B3, the expression of syndecan-1 was detected on tumor cell lines, such as 8226, U266, XG-1, XG-2, Daudi and Jurkat. The expression was also found on neuron stem cells. It was established that 4B3 mAb could inhibit XG-1 and XG-2 proliferation. The data not only determined that 4B3 mAb was a functional anti-human syndecan-1 mAb, but also indicated that syndecan-1 might be a valuable surface antigen and play an important role in regulation of tumor pathology and differentiation of neural stem cells. This novel antibody 4B3 may be value of study of tumor proliferation/survival mechanism and contributes to diagnosis and treatment of diverse diseases.

[Expression of human-mouse chimeric antibody against CD40 in CHO cell line and characterization of its function].

AIM: To investigate the stable expression of a chimeric antibody against CD40 moleculeèch-5C11éin CHO and its biological activity. METHODS: Human-mouse chimeric antibody against CD40 recombinant plasmid and mock plasmid were transfected into CHO cell line through lipofectamine mediation. Human kappa chain and Fc fragment of ch-5C11 were characterized by FACS and Western blot. The concentration of ch-5C11 in cell supernatants was detected by Lowry assay and the inhibitory effect of ch-5C11 on the proliferation of Daudi cells was detected by MTT assay. RESULTS: RT-PCR showed that target CHO cells integrated chimeric heavy chain and chimeric light chain gene. FACS and Western blot showed that ch-5C11 in cell supernatants maintained the binding activity and specificity to human CD40 molecule, and contained human kappa chain and Fc fragment. Cell supernatants were purified using protein G affinity chromatography. The concentration of human-mouse chimeric antibody against CD40 in cell supernatants was 0.535 mg/L. When co-cultured with B lymphoma cell line Daudi, ch-5C11 induced proliferation arrest of Daudi cells. CONCLUSION: The human-mouse chimeric antibody against CD40 can be expressed in CHO stably and effectively, which inhibits proliferation of Daudi.